You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
联康生物科技集团(00690.HK)产品再次被纳入2019年最新国家医保目录
格隆汇 08-22 20:49

格隆汇8月22日丨联康生物科技集团(00690.HK)发布公告,依据近日国家医疗保障局及国家人力资源和社会保障部于2019年8月20日发布的《国家基本医疗保险、工伤保险和生育保险药品目录(2019版)》通知(“医保目录”),集团的三唑类、重组人表皮生长因子类及格列奈类产品再次被纳入最新国家医保目录管理范围,该目录将于2020年1月1日起正式实施。集团主要销售的获专利生物药品金因肽(重组人表皮生长因子外用溶液(I))与获专利化学药品匹纳普(伏立康唑片)及博康泰(米格列奈钙片)的市场潜力预期将持续释放。

值得注意的是,对于是次目录内药品调整,过去地方医保部门在国家目录的基础上有15%的调整权利,但此次国家医疗保障局明确取消地方医保目录调整权,所以本次被纳入国家医保目录的各类品种将在各直辖市、省级医保政策实施中被更好地管理和保护并长期受益。

公司预期金因肽、匹纳普及博康泰再次被纳入医保目录后将有利于产品市场份额的扩大及市场布局的拓展,对集团今后的销量增长和长远发展产生积极作用。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account